Personalized cancer vaccine crosses the phase III life-and-death line! Moderna (MRNA.US) stock skyrocketed by 177% in a single day, and the mRNA chain welcomes its "second value awakening."

A leader in the mRNA vaccine field, Moderna (MRNA.US) saw its market capitalization double on Wednesday, with the stock price skyrocketing by 177% by the close of U.S. markets, driving significant increases in the stock prices of competitors in the biomedical and healthcare sectors. The company has achieved major success in the late-stage (Phase III) clinical trial of a cancer vaccine based on messenger RNA technology (mRNA), which it is developing in partnership with American pharmaceutical giant Merck & Co., Inc. (MRK.US), targeting patients with melanoma. As a testament to strong growth consensus for this biomedical leader focusing on late-stage Phase III trials, Wall Street investment heavyweight William Blair upgraded the vaccine manufacturers rating from "in line with the market" to "outperform." Moderna's CEO, Stphane Bancel, stated in a media interview that the personalized vaccine named "intismeran autogene" could be approved as early as 2027, pending regulatory review. Following this announcement, there has been extreme divergence on Wall Street: the highest new target price verified came from Bank of America Corp, where Alec Stranahan upgraded Moderna from "underperform" to "neutral, raising the target price from $40 to a staggering $170. He believes intismeran is a turning point for Moderna, transitioning it from an infectious disease vaccine company to a cancer platform company, unlocking the optional value of nine cancer trials and potentially alleviating long-term R&D investment and capital consumption pressures. Piper Sandler maintained an "overweight" rating, raising their target price from $77 to $167, while Goldman Sachs Group, Inc. raised theirs to $120. Based on the closing price of $62.96 before the positive announcement, a target price of $170 would imply a potential increase of about 170.0%. However, Modernas stock subsequently surged by 176.97% to $174.38 in one day, surpassing this highest target price and instead reflecting about a 2.5% potential downside. This somewhat indicates that scientific breakthroughs have fundamentally restructured the companys value, but it also means the stock price has already factored in considerable expectations of melanoma commercialization and cross-cancer success within a single day. The next phase of true valuation anchoring will shift from "whether it succeeds" to the Phase III risk ratio, the absolute survival benefits for patients, the probability of approval by 2027, and the replicability for other solid tumors. Why is Moderna's significant Phase III victory regarded as "a beacon of hope in human cancer treatment"? The core breakthrough achieved by Moderna and Merck & Co., Inc. is not merely the success of an ordinary vaccine but the clinical efficacy of personalized neoantigen therapy (INT) being verified for the first time in a randomized, double-blind, global Phase III trial: the INTerpath-001 trial included 1,137 patients with completely resected stage IIB-IV melanoma who still had a high risk of recurrence. The combination of intismeran autogene and Keytruda achieved the primary endpoint of recurrence-free survival (RFS) and the critical secondary endpoint of distant metastasis-free survival (DMFS), significantly outperforming Keytruda monotherapy, without any new safety signals. This trial represents the worlds first positive Phase III results for a personalized neoantigen therapy and the first successful entry into Phase III verification for an mRNA cancer treatment, significantly surpassing Keytruda, the standard treatment, in postoperative adjuvant therapy for melanoma. It is important to note that the previous Phase IIb study showed a 49% reduction in the risk of recurrence or death, and a 59% reduction in the risk of distant metastasis or death over five years; the specific risk ratio, absolute benefits, and overall survival (OS) data from this most recent Phase III trial have yet to be released. The underlying technology is not a preventative "universal cancer vaccine" aimed at everyone, but rather a treatment platform comprising "tumor sequencing neoantigen prediction personalized mRNA design precise immune activation": researchers read the unique mutation fingerprints of patients tumors, select up to 34 neoantigens, and encode them into synthetic mRNA. Once injected, human cells express these antigens, training cytotoxic T cells to recognize cancer cells; Keytruda then lifts the PD-1 immune checkpoint's inhibition on T cells, addressing the two major bottlenecks of accurately identifying tumors and sustained attacks. Moderna and Merck & Co., Inc.'s breakthrough cancer treatment achieving its primary endpoint is a significant boon for high-risk melanoma patients and could potentially open new pathways for solid tumors such as lung cancer, bladder cancer, kidney cancer, and pancreatic cancer. However, at this stage, it cannot be interpreted as humanity having conquered cancer and we must await complete Phase III data, overall survival benefits, regulatory review, as well as validation of custom vaccine production cycles, costs, and scalability of delivery. From COVID-19 vaccines to tumor immunotherapy: Moderna rewrites the mRNA valuation curve with its first Phase III victory. Moderna, which previously saw its stock price soar due to its mRNA vaccine amid the COVID-19 pandemic, has witnessed its latest trial results trigger stock price increases in its German competitor, BioNTech (BNTX.US), as well as American vaccine manufacturer Novavax (NVAX.US). Meanwhile, the biotech sector, represented by the SPDR S&P Biotech ETF (named XBI, XBI.US), has overall risen by more than 4%; if this rise continues, it will mark the ETF's best consecutive single-day intraday surge and strongest monthly price increase since March. This surge was driven by the success of a late-stage clinical trial. This trial evaluated the efficacy of intismeran used in combination with Merck & Co., Inc.'s (MRK) blockbuster drug Keytruda; the combination therapy achieved the primary endpoint of recurrence-free survival compared to Keytruda monotherapy, as well as the primary endpoint of distant metastasis-free survival. Merck & Co., Inc. (MRK.US) and Moderna (MRNA.US) indicated that the Phase III clinical trial named INTerpath-001 recruited over 1,100 high-risk melanoma patients with completely resected tumors, and highlighted that this is the first late-stage clinical trial in a similar melanoma treatment scenario to demonstrate efficacy superior to Keytruda. Senior analyst Myles Minter from William Blair wrote while upgrading Moderna's stock rating: The positive results from the INTerpath-001 study in melanoma adjuvant therapy also provide meaningful validation for intismerans efficacy in investigations for other cancers. The analyst noted that there are currently eight Phase II and III clinical trials assessing the efficacy of intismeran against various cancers, including a Phase III trial for non-small cell lung cancer, and two completed Phase II trials, respectively targeting renal cell carcinoma and bladder cancer. Minter indicated that results from the Phase II trial for renal cell carcinoma, expected by the end of this year, could serve as the next catalyst, as this study might have the potential to support registration filings. He also noted that the two companies are advancing their intismeran-related research under an agreement where profits are split 50/50. This technology transforms part of cancer treatment into a programmable bio-information assembly line: sequencing the patients tumor, using bioinformatics and machine learning to screen for new antigens most likely to be recognized by the immune system, and encoding up to 34 new antigens into exclusive mRNA; mRNA is responsible for training T cells to recognize the tumors mutation fingerprints, while Keytruda releases the PD-1 immune checkpoint brakes, allowing T cells to continue attacking residual cancer cells. Therefore, optimistic views such as those by Elon Musk, claiming that artificial RNA will turn disease into a software problem, focus on the platform's programmability, yet underestimate the complex biological constraints of antigen presentation, HLA variation, tumor microenvironments, and immune evasion. What ultimately determines the value of this platform is whether it can replicate from the highly immunogenic melanoma to non-small cell lung cancer, kidney cancer, and bladder cancer: Goldman Sachs Group, Inc. consequently raised the probability of success for melanoma to 100%, and for non-small cell lung cancer to 85%, estimating that peak global sales for these two indications could reach $4.3 billion and $6.6 billion respectively, not accounting for the total sales forecasts shared 50/50 with Merck & Co., Inc.